Fda advisory committee votes favorably that the data support arimoclomol as effective treatment for patients with niemann-pick disease type c

Celebration, fla., aug. 02, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a rare disease therapeutics company, today announced that the u.s. food and drug administration (fda) genetic metabolic diseases advisory committee (gemdac) voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with niemann-pick disease type c (npc).
ZVRA Ratings Summary
ZVRA Quant Ranking